Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Incidence of TRALI in Patients Undergoing Orthopedic-Oncology Surgery

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2009 by Tel-Aviv Sourasky Medical Center.
Recruitment status was:  Not yet recruiting
Information provided by:
Tel-Aviv Sourasky Medical Center Identifier:
First received: June 4, 2009
Last updated: NA
Last verified: June 2009
History: No changes posted
Currently Transfusion-related acute lung injury (TRALI) is the leading cause of transfusion-related mortality in the United States, and one of major post-transfusion complications. TRALI is defined as new ALI occurring within 6 hours from the onset of transfusion. It is manifested by acute dyspnea, hypoxemia and bilateral infiltrates in chest radiograph. TRALI may be caused by any blood product and is not dose-dependent. Associated risk factors include prolonged storage of blood products and underlying conditions such as severe IHD hematologic malignancies or active infections. Since TRALI has only recently been defined as a clinical entity, and its prevalence has been largely underestimated - the epidemiology of TRALI is not well established. Therefore the objective of this work is to study the incidence of TRALI in a patient population that receive blood products frequently, namely orthopedic-oncologic.

Pulmonary Edema

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: The Incidence of Transfusion-Related Acute Lung Injury (TRALI) Following Blood Product Transfusion in Patients Undergoing Elective Orthopedic-Oncology Procedures

Resource links provided by NLM:

Further study details as provided by Tel-Aviv Sourasky Medical Center:

Primary Outcome Measures:
  • The incidence of TRALI in patients undergoing orthopedic-oncology procedures, following blood product transfusion [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • The correlation between the incidence of TRALI and the age of blood product [ Time Frame: 2 years ]

Biospecimen Retention:   Samples With DNA
blood from arterial line to test for PaO2

Estimated Enrollment: 550
Study Start Date: August 2009
Estimated Study Completion Date: September 2011
Estimated Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients aged >18 years old, with ASA I-III, undergoing elective orthopedic-oncology procedures in the Sourasky Medical Center, and receiving blood products pre-, intra-, or post-operatively.

Inclusion Criteria:

  • Patients aged >18 years old, with ASA I-III, undergoing elective orthopedic-oncology procedures in the Sourasky Medical Center, and receiving blood products pre-, intra-, or post-operatively.

Exclusion Criteria:

  • Patients with a history of chronic renal insufficiency (creatinine > 1.5 of normal value), congestive heart failure, hepatic dysfunction, preexisting ALI, or acute infection.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00914784

Contact: Idit Matot, MD 97236974758
Contact: Yifat Klein, PhD 97236974093

Tel Aviv Sourasky medical center Not yet recruiting
Tel Aviv, Israel, 64239
Contact: Yifat Klein, PhD    9726974093   
Sub-Investigator: Shlomo Dadia, MD         
Sub-Investigator: Alex Gorodetsky, MD         
Sub-Investigator: Yifat Klein, PhD         
Principal Investigator: Idit Matot, MD         
Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
Study Chair: Idit Matot, MD Tel-Aviv Sourasky Medical Center
  More Information

Responsible Party: Prof Idit Matot, Department of anesthesia and intensive care, Tel-Aviv Sourasky Medical Center Identifier: NCT00914784     History of Changes
Other Study ID Numbers: TASMC-09-IM-0295-CTIL
Study First Received: June 4, 2009
Last Updated: June 4, 2009

Keywords provided by Tel-Aviv Sourasky Medical Center:
pulmonary infiltrates

Additional relevant MeSH terms:
Pulmonary Edema
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Lung Diseases processed this record on May 25, 2017